Related Experiment Video
Updated: Oct 11, 2025
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.8K
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
Ryan J Stubbins1,2, Aly Karsan3,4
1Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada.
Blood Cancer Journal
|December 5, 2021
Summary
New therapies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are showing promise by promoting cellular differentiation. Understanding this mechanism is key to developing more effective treatments with reduced toxicity.
Area of Science:
- Hematology
- Oncology
- Cellular Biology
Background:
- Blocked cellular differentiation is a hallmark of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
- Recent advancements include epigenetic therapies, IDH inhibitors, FLT3 inhibitors, and lenalidomide for MDS.
- Some novel therapies, while not designed for differentiation, function by inducing it.
Purpose of the Study:
- To review the current therapeutic landscape for MDS and AML.
- To examine the role of hematopoietic differentiation, inflammation, and aging in these diseases.
- To explore novel strategies for inducing differentiation in myeloid malignancies.
Main Methods:
- Review of current literature on MDS and AML therapies.
- Analysis of the mechanisms by which novel agents promote cellular differentiation.
- Discussion of the impact of inflammation and aging on treatment efficacy.
Main Results:
- Several novel therapies for MDS/AML, including epigenetic agents and targeted inhibitors, induce cellular differentiation.
- Differentiation induction is a significant mechanism of action for many new MDS/AML treatments.
- Understanding differentiation blockade is crucial for current therapy mechanisms and future drug development.
Conclusions:
- Relieving differentiation blockade is a critical therapeutic strategy for myeloid malignancies.
- Novel agents offer improved efficacy and reduced toxicity by targeting differentiation.
- Future treatments may explicitly target cellular differentiation for enhanced outcomes in MDS and AML.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
3.4K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.4K
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:27Tumor Immunotherapy
725
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725
02:50Combination Therapies and Personalized Medicine
5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
01:21Stem Cell Therapy for Tissue Regeneration
4.3K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.3K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K